Navidea Biopharmaceuticals Inc. announced that it has entered into an agreement with Nordion (Canada) Inc. to produce and supply (123) I-labeled NAV5001 for Navidea's late-phase clinical trials. The agreement focuses on Nordion's cGMP manufacturing and supply of NAV5001 clinical trial material to be produced at Nordion's Vancouver, British Columbia, facility. Accordingly, Nordion will radiolabel Navidea's precursor drug product with Iodine-123 to form [(123) I]NAV5001, manage the logistics and make arrangements for shipment of NAV5001 to third-party clinical trial sites on behalf of Navidea. The agreement may serve as a predecessor to a commercial supply arrangement in the future.

Navidea Biopharmaceuticals Inc. reported earnings results for the first quarter of 2013. For the first quarter of 2013, the company's net loss attributable to common shareholders was $7.3 million or $0.06 per share compared to a net loss attributable to common shareholders of $7 million or $0.07 per share for the first quarter of 2012. Loss from operations was $7 million compared to $6.5 million for the same period in 2012.

Effective May 1, 2013, the Board of Directors of Navidea Biopharmaceuticals Inc. appointed Mark J. Pykett, V.M.D., Ph.D. as Chief Executive Officer and Thomas H. Tulip, Ph.D. as President and Chief Business Officer to serve until his successor is duly elected, or until his earlier resignation or removal. As a result of the appointments described above, Dr. Tulip became the President of the company effective May 1, 2013. Pykett remains the company's Chief Executive Officer and principal executive officer. Prior to his appointment as President and Chief Business Officer, Dr. Tulip, age 60, had served as Executive Vice President and Chief Business Officer of the Company since June 2011. Dr. Tulip has held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. Most recently, as President, Alseres Molecular Imaging, Dr. Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS prior to Alseres, he was instrumental in the development, commercialization and international management of a nuclear cardiology franchise, successfully built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at Lantheus/BMS.